Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Go back to Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts| (NASDAQ: VRCA) | Delayed: 5.70 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.70 | 52 Week High | $ | |||
| Open | $5.70 | 52 Week Low | $ | |||
| Day High | $5.70 | P/E | N/A | |||
| Day Low | $5.70 | EPS | $ | |||
| Volume | 442 | |||||
